- Hepatitis B treatments and diagnostics are increasingly vital components of Asia-Pacific’s public health infrastructure, particularly across both urban and rural healthcare settings, due to rising infection awareness, expansion of diagnostic capabilities, and advancements in antiviral therapy accessibility
- The escalating demand for effective Hepatitis B management in the region is primarily fueled by national immunization programs, increasing HBV-HDV co-infection screening efforts, and the growing burden of chronic liver diseases, especially among aging populations in countries such as China and Japan
- China dominated the Asia-Pacific Hepatitis B Infection market with the largest revenue share of 34.7% in 2024, characterized by large-scale public health initiatives, robust vaccination coverage, and widespread access to diagnostic testing. The country has seen rapid improvements in treatment availability, especially for rural and high-risk populations, driven by government-backed health insurance schemes and liver disease awareness campaigns
- India is expected to be the fastest growing region in the Asia-Pacific Hepatitis B Infection Market The market benefits from government initiatives such as the Universal Immunization Programme, rising public awareness, and enhanced access to affordable diagnostics and generics, particularly in underserved regions. These factors collectively contribute to India’s growing role in driving regional market expansion
- The chronic hepatitis B segment dominated the Asia-Pacific Hepatitis B Infection market with a market share of 62.4% in 2024, driven by its long-term health implications, the growing number of diagnosed cases, and the need for extended antiviral therapy and liver monitoring programs
